Biomeme’s ultra-sensitive, highly accurate molecular detection technology makes host response an actionable and accessible diagnostic tool in the race against antibiotic misuse and Antimicrobial Resistance (AMR).
Our novel Host Response Test (HR-B/V) is the key to providing unparalleled sensitivity and reliability for providers differentiating between bacterial and viral infections.
Our versatile platform is built to be the end-to-end molecular detection solution to help providers with their antibiotic stewardship strategies and quality initiatives.
Performs like an advanced lab–no special equipment required.
Simultaneously measure 25 mRNA targets to detect the host gene response signature.
Administered prior to prescribing antibiotics — results in under an hour.
We are harnessing the potential of Host Response in diagnostics with our next-generation, automated Franklin ISP testing platform. Let’s examine what this new frontier means for providers and patients as we tackle, with data, the inappropriate use of antibiotics.*
Our test aspires to reduce antibiotic overuse and prevent antimicrobial resistance by helping healthcare providers distinguish accurately between bacterial and viral infections.
Providers can make informed treatment decisions quickly and with confidence as we aim to deliver results in less than an hour.
Accurate diagnosis of bacterial and viral infections can improve patient outcomes by enabling appropriate treatment to be prescribed.
Our Franklin ISP thermocycler and mobile app enable testing to be performed at the point-of-need or in central labs, making testing accessible in various settings.
Leveraging machine learning and host biology, our test offers a novel solution for the diagnosis, treatment, and management of infectious diseases, opening a new frontier in diagnostics.
Our COVID-19 testing facilities have mostly closed, but what they accomplished in three years lives on. Recently, we...
*Biomeme's HR-B/V Test is currently under development and is not approved/cleared by the FDA.